MA52231A - Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer - Google Patents

Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer

Info

Publication number
MA52231A
MA52231A MA052231A MA52231A MA52231A MA 52231 A MA52231 A MA 52231A MA 052231 A MA052231 A MA 052231A MA 52231 A MA52231 A MA 52231A MA 52231 A MA52231 A MA 52231A
Authority
MA
Morocco
Prior art keywords
inhibitors
cancer
treatment
combination
lif
Prior art date
Application number
MA052231A
Other languages
English (en)
French (fr)
Inventor
Folgueira Judit Anido
Teixidor Ester Bonfill
Johan Fransson
Garcia Monica Pascual
Rigol Ester Planas
Suarez Joan Seoane
Original Assignee
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron, Medimmune Ltd filed Critical Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Publication of MA52231A publication Critical patent/MA52231A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052231A 2018-04-12 2019-04-11 Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer MA52231A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18382248 2018-04-12
EP18382326 2018-05-14
EP18382360 2018-05-25
EP19382132 2019-02-22

Publications (1)

Publication Number Publication Date
MA52231A true MA52231A (fr) 2021-02-17

Family

ID=67060425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052231A MA52231A (fr) 2018-04-12 2019-04-11 Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer

Country Status (11)

Country Link
US (1) US20210130453A1 (https=)
EP (1) EP3774895A1 (https=)
JP (2) JP7423598B2 (https=)
KR (1) KR20210021287A (https=)
CN (1) CN112585164A (https=)
AU (1) AU2019251289B2 (https=)
CA (1) CA3096779A1 (https=)
IL (1) IL277918A (https=)
MA (1) MA52231A (https=)
SG (1) SG11202009966SA (https=)
WO (1) WO2019197903A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
WO2021183370A1 (en) * 2020-03-11 2021-09-16 Purdue Research Foundation Compounds with immunomodulatory activity and therapeutic uses thereof
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof

Also Published As

Publication number Publication date
AU2019251289A1 (en) 2020-11-26
CN112585164A (zh) 2021-03-30
AU2019251289A8 (en) 2021-01-14
EP3774895A1 (en) 2021-02-17
WO2019197903A1 (en) 2019-10-17
US20210130453A1 (en) 2021-05-06
CA3096779A1 (en) 2019-10-17
AU2019251289B2 (en) 2024-01-18
IL277918A (en) 2020-11-30
JP7423598B2 (ja) 2024-01-29
SG11202009966SA (en) 2020-11-27
WO2019197903A8 (en) 2020-02-20
JP2024054138A (ja) 2024-04-16
KR20210021287A (ko) 2021-02-25
JP2021521274A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
MA52231A (fr) Combinaison d'inhibiteurs de lif et d'inhibiteurs de l'axe pd-1 pour une utilisation dans le traitement du cancer
FR25C1041I1 (fr) Elafibranor pour l'utilisation dans le traitement de la cholangite biliaire primitive
MA55965A (fr) Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
EP3430057A4 (en) USE OF APE1 / REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATING CANCER
MA50073A (fr) Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine
EP3796920A4 (en) TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER
MA52661A (fr) Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
MA46995A (fr) Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
EP3653630A4 (en) ENDOCYCLIC THIAMIDINOAMIDE-ARYLAMIDE COMPOUND AND USE THEREOF FOR TREATMENT OF HEPATITIS B.
EP3509594C0 (en) A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis
MA56184A (fr) Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
EP4076444A4 (en) INDAZOL DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES
MA52971A (fr) Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
EP3403675A4 (en) ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA
EP3848022C0 (en) THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
EP3496743A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ARGININE DEPLETION AND IMMUNOLOGICAL ACTIVE SUBSTANCES
IL289758A (en) Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
EP3845252A4 (en) USE OF ANTI-HER2 ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF UROTHELIAL CANCER
EP3813870C0 (en) CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
EP3386949A4 (en) GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN